585 related articles for article (PubMed ID: 16192600)
1. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
3. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
4. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
6. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
7. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
8. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
9. [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991].
Zintl F; Malke H; Reimann M; Hermann J; Domula M; Dörffel W; Eggers G; Exadaktylos P; Hilgenfeld E; Kotte W
Klin Padiatr; 1992; 204(4):221-9. PubMed ID: 1518257
[TBL] [Abstract][Full Text] [Related]
10. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
11. [Long-term follow-up of 2 therapeutic programs for the treatment of high-risk childhood acute lymphoblastic leukemia. Experience at the 20 de Noviembre National Medical Center].
de Diego-Floreschapa J; López-Hernández M; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
Gac Med Mex; 1999; 135(3):253-8. PubMed ID: 10425822
[TBL] [Abstract][Full Text] [Related]
12. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
Clavell LA; Gelber RD; Cohen HJ; Hitchcock-Bryan S; Cassady JR; Tarbell NJ; Blattner SR; Tantravahi R; Leavitt P; Sallan SE
N Engl J Med; 1986 Sep; 315(11):657-63. PubMed ID: 2943992
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
15. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
16. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
17. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
18. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).
Kamps WA; Bökkerink JP; Hakvoort-Cammel FG; Veerman AJ; Weening RS; van Wering ER; van Weerden JF; Hermans J; Slater R; van den Berg E; Kroes WG; van der Does-van den Berg A
Leukemia; 2002 Jun; 16(6):1099-111. PubMed ID: 12040440
[TBL] [Abstract][Full Text] [Related]
19. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
20. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
